A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status
A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the
Biological Activity of AZD8931 in Patients with Early Breast Cancer who are Ineligible for
Treatment with trastuzumab as defined by IHC status
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science
Comparison of the effects of AZD8931 versus placebo on cytoplasmic p-MAPK after 7 days or more days of treatment
Day 7 - Day 14
Yes
Serban Ghiorghiu, M.D.
Study Director
Internal
Germany: Ministry of Health
D0102C00019
NCT01596530
June 2012
May 2013
Name | Location |
---|